Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of "Moderate Buy" from Brokerages

Key Points

• Elanco Animal Health has a “Moderate Buy” consensus rating from 13 analysts, including nine buys and one strong buy. The average 12-month price target is $29.09, above the reported share price of $22.06.
• The company exceeded quarterly expectations, reporting adjusted EPS of $0.34 versus the $0.27 consensus and revenue of $1.37 billion, up 10.2% year over year. Management guided for third-quarter EPS of $0.19–$0.22 and full-year 2026 EPS of $1.10–$1.16.
• Elanco insiders recently purchased shares, including CEO Jeffrey N. Simmons and insider Rajeev A. Modi, while institutional investors own 97.48% of the stock.

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the thirteen ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $29.0909.

A number of research firms have recently weighed in on ELAN. TD Cowen raised their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, June 18th. UBS Group upped their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a report on Thursday. Piper Sandler reiterated an "overweight" rating on shares of Elanco Animal Health in a report on Monday, June 29th. JPMorgan Chase & Co. increased their target price on shares of Elanco Animal Health from $28.00 to $30.00 and gave the stock an "overweight" rating in a research report on Thursday, May 7th. Finally, Weiss Ratings upgraded Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a report on Friday, July 31st.

Elanco Animal Health Trading Down 8.9%

Shares of NYSE ELAN opened at $22.06 on Friday. The business has a 50 day simple moving average of $24.70 and a 200 day simple moving average of $24.09. Elanco Animal Health has a 52 week low of $16.15 and a 52 week high of $27.98. The stock has a market cap of $11.02 billion, a price-to-earnings ratio of -53.80, a PEG ratio of 1.45 and a beta of 1.67. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.12 and a current ratio of 2.05.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.07. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company's revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter last year, the firm earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. On average, research analysts predict that Elanco Animal Health will post 1.12 earnings per share for the current fiscal year.

Insider Transactions at Elanco Animal Health

In related news, insider Rajeev A. Modi acquired 4,911 shares of the stock in a transaction dated Friday, May 15th. The shares were acquired at an average price of $20.35 per share, with a total value of $99,938.85. Following the acquisition, the insider owned 160,812 shares in the company, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Jeffrey N. Simmons acquired 4,971 shares of the business's stock in a transaction that occurred on Friday, May 15th. The stock was bought at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. This represents a 2.98% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 1.14% of the company's stock.

Hedge Funds Weigh In On Elanco Animal Health

A number of institutional investors have recently modified their holdings of the company. NewEdge Advisors LLC boosted its holdings in shares of Elanco Animal Health by 133.7% during the 4th quarter. NewEdge Advisors LLC now owns 1,096 shares of the company's stock worth $25,000 after buying an additional 627 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in Elanco Animal Health in the 2nd quarter valued at $38,000. Root Financial Partners LLC raised its holdings in Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company's stock worth $40,000 after acquiring an additional 592 shares during the period. Uniplan Investment Counsel Inc. bought a new position in Elanco Animal Health in the 4th quarter worth $41,000. Finally, Torren Management LLC bought a new position in Elanco Animal Health in the 4th quarter worth $46,000. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source